FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149184447> ?p ?o ?g. }

• W2149184447 endingPage "84" @default.
• W2149184447 startingPage "76" @default.
• W2149184447 abstract "ObjectiveTo determine the long-term outcomes of mitral valvuloplasty for myxomatous valve disease, rheumatic valve disease, and functional mitral regurgitation.MethodsA total of 1503 patients underwent mitral valvuloplasty by a single surgeon between February 1972 and April 2008 and were retrospectively reviewed for short- and long-term results. Overall mean age was 60.3 ± 13.7 years, and 57% were male. The cause was rheumatic in 193 patients, myxomatous in 1042 patients, and ischemic and nonischemic functional mitral regurgitation in 236 patients. Ring annuloplasty was performed in 1306 patients (87%). Commissurotomy was the primary repair for rheumatic valves, posterior leaflet resection and reconstruction was the most common repair for myxomatous valves (527/1042 [51%]), and ring reduction annuloplasty was the primary operation for functional mitral regurgitation.ResultsThe 30-day mortality was 19 of 1503 patients (1.3%) and significantly higher in the functional mitral regurgitation group (11/236 patients, 4.7% vs 0.5% in the rheumatic group and 0.6% in the myxomatous group, P < .01). The 10-, 20-, and 30-year survivals were similar for the rheumatic and myxomatous groups (77%, 56%, and 39% vs 79%, 62%, and 52%, respectively) but significantly less for the functional mitral regurgitation group (44%, 4%, and 0%, respectively, log-rank P < .0001). The 10- and 20-year freedom from reoperation rates were significantly better for the myxomatous group than for the rheumatic group (90% and 82% vs 66% and 34%, log-rank P < .0001), with a 30-year freedom from reoperation of only 10% for rheumatic repair. In the myxomatous group, freedom from reoperation was lower in patients with anterior leaflet pathology (P = .0008).ConclusionFollow-up data to 36 years demonstrate that cause strongly determines survival and durability of mitral valvuloplasty; patients with rheumatic valve disease who survive more than 20 years require reoperation, whereas functional mitral regurgitation carries the highest short- and long-term mortality rates and lowest freedom from reoperation. Mitral valvuloplasty for myxomatous valves demonstrates the longest durability, with many patients free from reoperation at 30 years. To determine the long-term outcomes of mitral valvuloplasty for myxomatous valve disease, rheumatic valve disease, and functional mitral regurgitation. A total of 1503 patients underwent mitral valvuloplasty by a single surgeon between February 1972 and April 2008 and were retrospectively reviewed for short- and long-term results. Overall mean age was 60.3 ± 13.7 years, and 57% were male. The cause was rheumatic in 193 patients, myxomatous in 1042 patients, and ischemic and nonischemic functional mitral regurgitation in 236 patients. Ring annuloplasty was performed in 1306 patients (87%). Commissurotomy was the primary repair for rheumatic valves, posterior leaflet resection and reconstruction was the most common repair for myxomatous valves (527/1042 [51%]), and ring reduction annuloplasty was the primary operation for functional mitral regurgitation. The 30-day mortality was 19 of 1503 patients (1.3%) and significantly higher in the functional mitral regurgitation group (11/236 patients, 4.7% vs 0.5% in the rheumatic group and 0.6% in the myxomatous group, P < .01). The 10-, 20-, and 30-year survivals were similar for the rheumatic and myxomatous groups (77%, 56%, and 39% vs 79%, 62%, and 52%, respectively) but significantly less for the functional mitral regurgitation group (44%, 4%, and 0%, respectively, log-rank P < .0001). The 10- and 20-year freedom from reoperation rates were significantly better for the myxomatous group than for the rheumatic group (90% and 82% vs 66% and 34%, log-rank P < .0001), with a 30-year freedom from reoperation of only 10% for rheumatic repair. In the myxomatous group, freedom from reoperation was lower in patients with anterior leaflet pathology (P = .0008). Follow-up data to 36 years demonstrate that cause strongly determines survival and durability of mitral valvuloplasty; patients with rheumatic valve disease who survive more than 20 years require reoperation, whereas functional mitral regurgitation carries the highest short- and long-term mortality rates and lowest freedom from reoperation. Mitral valvuloplasty for myxomatous valves demonstrates the longest durability, with many patients free from reoperation at 30 years." @default.
• W2149184447 created "2016-06-24" @default.
• W2149184447 creator A5047157487 @default.
• W2149184447 creator A5051994882 @default.
• W2149184447 creator A5059697925 @default.
• W2149184447 creator A5060115125 @default.
• W2149184447 creator A5061528861 @default.
• W2149184447 creator A5078955131 @default.
• W2149184447 date "2010-01-01" @default.
• W2149184447 modified "2023-10-17" @default.
• W2149184447 title "Four decades of experience with mitral valve repair: Analysis of differential indications, technical evolution, and long-term outcome" @default.
• W2149184447 cites W1941338328 @default.
• W2149184447 cites W1974787130 @default.
• W2149184447 cites W1975237554 @default.
• W2149184447 cites W1975556916 @default.
• W2149184447 cites W1982921794 @default.
• W2149184447 cites W2008924366 @default.
• W2149184447 cites W2023512712 @default.
• W2149184447 cites W2030042551 @default.
• W2149184447 cites W2037782092 @default.
• W2149184447 cites W2038910702 @default.
• W2149184447 cites W2043017734 @default.
• W2149184447 cites W2047495821 @default.
• W2149184447 cites W205109014 @default.
• W2149184447 cites W2054401435 @default.
• W2149184447 cites W2054695123 @default.
• W2149184447 cites W2059743389 @default.
• W2149184447 cites W2077147205 @default.
• W2149184447 cites W2093542120 @default.
• W2149184447 cites W2096732194 @default.
• W2149184447 cites W2132118967 @default.
• W2149184447 cites W2160602669 @default.
• W2149184447 cites W2191399290 @default.
• W2149184447 cites W2290277945 @default.
• W2149184447 cites W2315919853 @default.
• W2149184447 cites W2397470435 @default.
• W2149184447 cites W4237177705 @default.
• W2149184447 cites W4321060017 @default.
• W2149184447 doi "https://doi.org/10.1016/j.jtcvs.2009.08.058" @default.
• W2149184447 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19931098" @default.
• W2149184447 hasPublicationYear "2010" @default.
• W2149184447 type Work @default.
• W2149184447 sameAs 2149184447 @default.
• W2149184447 citedByCount "136" @default.
• W2149184447 countsByYear W21491844472012 @default.
• W2149184447 countsByYear W21491844472013 @default.
• W2149184447 countsByYear W21491844472014 @default.
• W2149184447 countsByYear W21491844472015 @default.
• W2149184447 countsByYear W21491844472016 @default.
• W2149184447 countsByYear W21491844472017 @default.
• W2149184447 countsByYear W21491844472018 @default.
• W2149184447 countsByYear W21491844472019 @default.
• W2149184447 countsByYear W21491844472020 @default.
• W2149184447 countsByYear W21491844472021 @default.
• W2149184447 countsByYear W21491844472022 @default.
• W2149184447 countsByYear W21491844472023 @default.
• W2149184447 crossrefType "journal-article" @default.
• W2149184447 hasAuthorship W2149184447A5047157487 @default.
• W2149184447 hasAuthorship W2149184447A5051994882 @default.
• W2149184447 hasAuthorship W2149184447A5059697925 @default.
• W2149184447 hasAuthorship W2149184447A5060115125 @default.
• W2149184447 hasAuthorship W2149184447A5061528861 @default.
• W2149184447 hasAuthorship W2149184447A5078955131 @default.
• W2149184447 hasBestOaLocation W21491844471 @default.
• W2149184447 hasConcept C126322002 @default.
• W2149184447 hasConcept C141071460 @default.
• W2149184447 hasConcept C164705383 @default.
• W2149184447 hasConcept C2777244179 @default.
• W2149184447 hasConcept C2777543888 @default.
• W2149184447 hasConcept C2780679668 @default.
• W2149184447 hasConcept C2780870192 @default.
• W2149184447 hasConcept C2993373945 @default.
• W2149184447 hasConcept C71924100 @default.
• W2149184447 hasConceptScore W2149184447C126322002 @default.
• W2149184447 hasConceptScore W2149184447C141071460 @default.
• W2149184447 hasConceptScore W2149184447C164705383 @default.
• W2149184447 hasConceptScore W2149184447C2777244179 @default.
• W2149184447 hasConceptScore W2149184447C2777543888 @default.
• W2149184447 hasConceptScore W2149184447C2780679668 @default.
• W2149184447 hasConceptScore W2149184447C2780870192 @default.
• W2149184447 hasConceptScore W2149184447C2993373945 @default.
• W2149184447 hasConceptScore W2149184447C71924100 @default.
• W2149184447 hasIssue "1" @default.
• W2149184447 hasLocation W21491844471 @default.
• W2149184447 hasLocation W21491844472 @default.
• W2149184447 hasOpenAccess W2149184447 @default.
• W2149184447 hasPrimaryLocation W21491844471 @default.
• W2149184447 hasRelatedWork W1996710510 @default.
• W2149184447 hasRelatedWork W2053507643 @default.
• W2149184447 hasRelatedWork W2073476060 @default.
• W2149184447 hasRelatedWork W2099845815 @default.
• W2149184447 hasRelatedWork W2486006457 @default.
• W2149184447 hasRelatedWork W2514330639 @default.
• W2149184447 hasRelatedWork W2778287432 @default.
• W2149184447 hasRelatedWork W3001059029 @default.
• W2149184447 hasRelatedWork W3145510652 @default.
• W2149184447 hasRelatedWork W94709752 @default.
• W2149184447 hasVolume "139" @default.

• next